Responses of smoking and nonsmoking cancer patients to drug treatment

Wang, Lishi; Feng, Helin; Li, Jing; Liu, FengXia; Liu, Qingyi; Ji, Jiafu; Postlethwaite, Arnold E.; Gu, Weikuan; Shan, Baoen

doi:10.1097/md.0000000000022104

Cited by 1 publication

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review and network meta-analysis have been used to analyze the response of smokers to drug treatment in cancer patients in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [ 26 ]. Ethical approval was not required for this study since it involved data analysis.…”

Section: Methodology and Criteriamentioning

confidence: 99%

“…We followed our procedure for the bias analysis from our protocol [ 26 ]. In general, either PFS or OS was provided from the studies.…”

Section: Methodology and Criteriamentioning

confidence: 99%

“…Thirdly, since most of the trials did not provide data separately for current and former smokers, it is not clear whether current smokers differ from former smokers, or, if former smokers may not respond as well as non-smokers. Two trials suggested that current smokers fared much better than former smokers [ 69 ], while one suggested the contrary [ 26 , 31 ].…”

Section: Conclusion Remarks and New Questionsmentioning

confidence: 99%

See 2 more Smart Citations

From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?

Wang

FengXia

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

Whether smokers respond to anti-cancer drugs differently than non-smokers remains controversial. The objective of this study is to explore whether the better response of the smokers is specific to therapy of anti-PD-1/PD-L1, anti-checkpoint inhibitor, individual drugs on the cell surface, or lung cancer. Our results showed that among all non-small cell lung cancer (NSCLC) patients, when the data from anti-PD-1/PD-L1, anti-CTLA-4, and anti-MUC1 drugs are combined, the mean hazard ratios (HR) of smokers and non-smokers were 0.751 and 1.016, respectively. A meta-analysis with a fixed effect (FE) model indicated that the smokers have an HR value of 0.023 lower than that of the non-smokers. A stratified subgroup meta-analysis indicated that when treated with anti-CTLA-4 drugs, smokers had reduced HR values of 0.152 and 0.165 on average and FE model meta-analysis, respectively. When treated with an anti-MUC1 drug, smokers had reduced HR values of 1.563 and 0.645, on average and FE model meta-analysis, respectively. When treated with a combination of nivolumab and ipilimumab drugs, smokers had, on average, reduced HR and FE model meta-analysis values (0.257 and 0.141), respectively. Smoking is a clinical response predictor for anti-PD/PD-L1 monotherapy or first-line treatment in lung, urothelial carcinoma, and head and neck cancer. Smokers treated with other drugs have shown worse responses in comparison to non-smokers. These data suggest that, along with the progress in the development of new drugs for cancer, drugs acting on specific genotypes of smokers likely will arise.

show abstract

Section: Methodology and Criteriamentioning

confidence: 99%

“…We followed our procedure for the bias analysis from our protocol [ 26 ]. In general, either PFS or OS was provided from the studies.…”

Section: Methodology and Criteriamentioning

confidence: 99%